Synex Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 06-07-2024
- Paid Up Capital ₹ 1.00 M
as on 06-07-2024
- Company Age 40 Year, 8 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 1.60 M
as on 06-07-2024
- Satisfied Charges ₹ 1.38 Cr
as on 06-07-2024
- Revenue %
(FY 2020)
- Profit 80.64%
(FY 2020)
- Ebitda 80.24%
(FY 2020)
- Net Worth -0.80%
(FY 2020)
- Total Assets -0.01%
(FY 2020)
About Synex Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹1.60 M. The company has closed loans amounting to ₹1.38 Cr, as per Ministry of Corporate Affairs (MCA) records.
Hetal Sanghavi and Hemant Gandhi serve as directors at the Company.
- CIN/LLPIN
U24239MH1984PTC032614
- Company No.
032614
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Apr 1984
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Synex Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Hetal Sanghavi  | Director | 02-Jul-2003 | Current |
| Hemant Gandhi | Director | 07-Apr-1984 | Current |
Financial Performance of Synex Pharmaceuticals.
Synex Pharmaceuticals Pvt Ltd, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 80.64% increase in profit. The company's net worth dipped by a decrease of 0.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Synex Pharmaceuticals?
In 2019, Synex Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Joy Frozen Foods Private LimitedActive 54 years 11 monthsHetal Sanghavi and Hemant Gandhi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 25 Jul 1995 | ₹0.20 M | Open |
The Maharashtra Staet Financial Corp. Creation Date: 14 Feb 1985 | ₹1.40 M | Open |
State Bank Of India Creation Date: 05 Apr 1999 | ₹7.50 M | Satisfied |
How Many Employees Work at Synex Pharmaceuticals?
Unlock and access historical data on people associated with Synex Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Synex Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Synex Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
